ClinicalTrials.gg
CompletedNCT02278354Updated Sep 10, 2020Results posted

Tau Imaging in Professional Fighters

A Phase 1 interventional study of Flortaucipir F18 and Brain PET scan in Alzheimer's Disease, sponsored by Avid Radiopharmaceuticals. Completed at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-09-10.

Sponsored by Avid Radiopharmaceuticals (part of Eli Lilly and Company) · Phase 1, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
35
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing flortaucipir in Alzheimer Disease — 4 open to participants now, 4 under way, none of them phase 3. flortaucipir · Alzheimer Disease.

Enrollment
15th of 22
35 · median 70
Started
2015
with 3 others
Phase 1
10 of 22
2 open now
Registered
5th of 22
by date
Lead sponsor
15 of 22
Avid Radiopharmaceuticals

Among the 22 studies testing flortaucipir in Alzheimer Disease, this one is the 15th largest by enrollment, is one of 4 that started in 2015, is one of 10 in phase 1, and was the 5th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

4 of the 22 studies testing flortaucipir in Alzheimer Disease are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

About flortaucipir

flortaucipir: first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing flortaucipir in Alzheimer Disease, or all of them as a file.
02

Study summary

Subjects enrolled in the Professional Fighters Brain Health Study (PFBHS) will receive flortaucipir to explore its use as a biomarker for brain injury related to repetitive head trauma and to examine the relationship between clinical presentation and tau deposition.

03

Conditions studied

  • Alzheimer's Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All Subjects

  • Currently enrolled in the PFBHS protocol and have participated in a minimum of 10 professional fights
  • Can tolerate Positron Emission Tomography (PET) scan procedures
  • Have the ability to provide

Subjects with cognitive impairment

  • Have subjective cognitive complaints or objective decline or impairment as determined by the investigator

Exclusion criteria

Exclusion Criteria:

  • Have behavior dysfunction that is likely to interfere with imaging
  • Are claustrophobic or otherwise unable to tolerate the imaging procedure
  • Have current cardiovascular disease or clinically significant abnormalities on screening
  • A history of additional risk factors for Torsades de Pointes (TdP) or are taking drugs that are known to cause -prolongation
  • Have a current clinically significant infectious disease, endocrine or metabolic disease, pulmonary, renal or hepatic impairment, or cancer
  • Have had a non-study related radiopharmaceutical imaging or treatment procedure within 7 days prior to the study imaging session
  • Have current drug or alcohol dependence or alcohol dependence within the past 2 years
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Active Professional Fighters

    Active professional fighters (with and without cognitive impairment) receiving a flortaucipir PET scan

    Drug: Flortaucipir F18 · Procedure: Brain PET scan

  • Experimental
    Retired Professional Fighters

    Retired professional fighters (with and without cognitive impairment) receiving a flortaucipir PET scan

    Drug: Flortaucipir F18 · Procedure: Brain PET scan

Interventions

  • IV injection, 370 megabecquerel (MBq) (10 mCi)

    Also known as: [F-18]T807, 18F-AV-1451, LY3191748, Tauvid

  • ProcedureBrain PET scan

    positron emission tomography (PET) scan of the brain 75-105 minutes post injection

06

What researchers measure

Primary outcomes

  1. Flortaucipir Imaging (Quantitative) Between Cognitive Groups

    Standard Uptake Value Ratio (SUVr) by subject enrollment group (cognitive impaired/normal) across weighted cortical average, frontal, temporal, parietal, and occipital brain regions. For SUVr, a value of 1 or lower signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain.

    Time frame: baseline scan

  2. Flortaucipir Imaging (Quantitative) Between Fighter Groups

    Standard Uptake Value Ratio (SUVr) by subject enrollment group (active fighter/retired fighter) across weighted cortical average, frontal, temporal, parietal, and occipital brain regions. For SUVr, a value of 1 or lower signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain.

    Time frame: baseline scan

  3. Flortaucipir Imaging (Qualitative) Between Cognitive Groups

    Qualitative read results (no, mild, moderate, or intense uptake) compared between cognitively impaired (CI) and cognitively normal (CN) groups.

    Time frame: baseline scan

  4. Flortaucipir Imaging (Qualitative) Between Fighter Groups

    Qualitative read results (no, mild, moderate, or intense uptake) compared between active and retired fighter groups

    Time frame: baseline scan

07

Results

Posted Sep 10, 2020

Participant flow

Enrollment occurred between Feb 2015 and Feb 2017

Participant flow — Overall Study
MilestoneActive Professional FightersRetired Professional Fighters
Started1223
Flortaucipir pet scan1020
Completed820
Not completed43
Withdrew: Lost to follow-up22
Withdrew: Withdrawal by subject01
Withdrew: <10 professional fights20

Outcome measures

PrimaryFlortaucipir Imaging (Quantitative) Between Cognitive Groups

Standard Uptake Value Ratio (SUVr) by subject enrollment group (cognitive impaired/normal) across weighted cortical average, frontal, temporal, parietal, and occipital brain regions. For SUVr, a value of 1 or lower signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain.

Time frame:
baseline scan
Reported as:
Least squares mean · standardized uptake value ratio (SUVr)
Flortaucipir Imaging (Quantitative) Between Cognitive Groups
standardized uptake value ratio (SUVr)Cognitively Impaired FightersCognitively Normal Fighters
Weighted cortical average1.0048 (0.977 to 1.0327)0.971 (0.9401 to 1.002)
Frontal0.9731 (0.9394 to 1.0068)0.9357 (0.8983 to 0.9732)
Temporal0.9867 (0.9425 to 1.0309)0.9305 (0.8812 to 0.9797)
Parietal0.9472 (0.9097 to 0.9847)0.9288 (0.8871 to 0.9705)
Occipital0.9513 (0.912 to 0.9906)0.9247 (0.8809 to 0.9684)
PrimaryFlortaucipir Imaging (Quantitative) Between Fighter Groups

Standard Uptake Value Ratio (SUVr) by subject enrollment group (active fighter/retired fighter) across weighted cortical average, frontal, temporal, parietal, and occipital brain regions. For SUVr, a value of 1 or lower signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain.

Time frame:
baseline scan
Reported as:
Least squares mean · standardized uptake value ratio (SUVr)
Flortaucipir Imaging (Quantitative) Between Fighter Groups
standardized uptake value ratio (SUVr)Active Professional FightersRetired Professional Fighters
Weighted cortical average0.9965 (0.963 to 1.0299)0.9794 (0.9546 to 1.0042)
Frontal0.9816 (0.9411 to 1.022)0.9273 (0.8973 to 0.9572)
Temporal0.9838 (0.9306 to 1.0369)0.9334 (0.894 to 0.9728)
Parietal0.9623 (0.9172 to 1.0073)0.9137 (0.8803 to 0.9471)
Occipital0.9632 (0.916 to 1.0105)0.9127 (0.8777 to 0.9478)
PrimaryFlortaucipir Imaging (Qualitative) Between Cognitive Groups

Qualitative read results (no, mild, moderate, or intense uptake) compared between cognitively impaired (CI) and cognitively normal (CN) groups.

Time frame:
baseline scan
Reported as:
Count of participants · Participants
Flortaucipir Imaging (Qualitative) Between Cognitive Groups
ParticipantsCognitively Impaired FightersCognitively Normal Fighters
No Uptake1612
Mild Uptake20
Moderate Uptake00
Intense Uptake00
PrimaryFlortaucipir Imaging (Qualitative) Between Fighter Groups

Qualitative read results (no, mild, moderate, or intense uptake) compared between active and retired fighter groups

Time frame:
baseline scan
Reported as:
Count of participants · Participants
Flortaucipir Imaging (Qualitative) Between Fighter Groups
ParticipantsActive Professional FightersRetired Professional Fighters
No Uptake1018
Mild Uptake02
Moderate Uptake00
Intense Uptake00

Adverse events

Collected over End of study for AE reporting was 48 hours after the last study drug administration.. Non-serious events are listed at a 1.0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Active Professional Fighters0/10 (0%)0/10 (0%)0/10 (0%)
Retired Professional Fighters0/20 (0%)0/20 (0%)2/20 (10%)
Most frequent other events
Most frequent other events
EventActive Professional FightersRetired Professional Fighters
diarrhoeaGastrointestinal disorders0/101/20
epistaxisRespiratory, thoracic and mediastinal disorders0/101/20

Baseline characteristics

Only includes subjects who received a flortaucipir PET scan in the study.

Age, Continuous
Age, Continuous(years)Active Professional FightersRetired Professional FightersTotal
Mean31.7 ± 4.2747.6 ± 10.2142.3 ± 11.49
Sex: Female, Male
Sex: Female, Male(Participants)Active Professional FightersRetired Professional FightersTotal
Female000
Male102030
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Active Professional FightersRetired Professional FightersTotal
Hispanic or Latino1910
Not Hispanic or Latino91120
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Active Professional FightersRetired Professional FightersTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American5712
White31316
More than one race000
Unknown or Not Reported000
Other202
Region of Enrollment
Region of Enrollment(participants)Active Professional FightersRetired Professional FightersTotal
United States102030
Amyloid status
Amyloid status(Participants)Active Professional FightersRetired Professional FightersTotal
Amyloid negative11415
Amyloid positive000
08

Study locations

1 site
  • Cleveland Clinic Lou Ruvo Center for Brain Health
    Las Vegas, Nevada 89106, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2015 to primary completion in Feb 2017, 23 months.

Results were first posted in Sep 2020, 3 years 7 months after primary completion.

Of 161 industry-sponsored phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's 23 months is above that.

Counting every sponsor, half of 234 studies reached it within 18 months; a quarter within 7 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2014
First posted
Oct 30, 2014
StartActual
Feb 18, 2015
Primary completionActual
Feb 3, 2017
CompletionActual
Feb 3, 2017
Results first posted
Sep 10, 2020
Last update
Sep 10, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02278354
Responsible party
Sponsor
First posted
Oct 30, 2014
Start date
Feb 18, 2015
Primary completion
Feb 3, 2017
Completion
Feb 3, 2017
Results posted
Sep 10, 2020
Last update
Sep 10, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Flortaucipir

Start the discussion